In addition to our analysis of the TCGA CNS dataset, we reanalyzed available data from two GEO datasets (GSE7696, consisting of 76 IDH wildtype grade 4 GBM cases, and GSE107850, consisting of 166 IDH mutant NOS (not otherwise specified) grade 2 cases) to investigate the impact of RYK gene expression and MGMT methylation on the progression-free survival (PFS) and OS of patients who received TMZ treatment. The gene discussed is RYK; the disease is glioblastoma.